These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 8332946

  • 1. Neurochemical correlates of behavioral sensitization following repeated apomorphine treatment: assessment of the role of D1 dopamine receptor stimulation.
    Rowlett JK, Mattingly BA, Bardo MT.
    Synapse; 1993 Jun; 14(2):160-8. PubMed ID: 8332946
    [Abstract] [Full Text] [Related]

  • 2. Repeated quinpirole treatment: locomotor activity, dopamine synthesis, and effects of selective dopamine antagonists.
    Rowlett JK, Mattingly BA, Bardo MT.
    Synapse; 1995 Jul; 20(3):209-16. PubMed ID: 7570352
    [Abstract] [Full Text] [Related]

  • 3. Effects of SKF-38393, a dopamine D1 receptor agonist on expression of amphetamine-induced behavioral sensitization and expression of immediate early gene arc in prefrontal cortex of rats.
    Moro H, Sato H, Ida I, Oshima A, Sakurai N, Shihara N, Horikawa Y, Mikuni M.
    Pharmacol Biochem Behav; 2007 May; 87(1):56-64. PubMed ID: 17499349
    [Abstract] [Full Text] [Related]

  • 4. Repeated intra-ventral tegmental area administration of SKF-38393 induces behavioral and neurochemical sensitization to a subsequent cocaine challenge.
    Pierce RC, Born B, Adams M, Kalivas PW.
    J Pharmacol Exp Ther; 1996 Jul; 278(1):384-92. PubMed ID: 8764374
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ, Albers LJ, Le H, Creese I.
    J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
    [Abstract] [Full Text] [Related]

  • 7. Impact of metyrapone on MK-801-induced alterations in the rat dopamine D1 receptors.
    Czyrak A, Maćkowiak M, Fijał K, Chocyk A, Wedzony K.
    Pol J Pharmacol; 1997 Sep; 49(5):305-16. PubMed ID: 9566029
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
    Neal-Beliveau BS, Joyce JN.
    Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
    Wirtshafter D, Osborn CV.
    Eur J Pharmacol; 2005 Dec 28; 528(1-3):88-94. PubMed ID: 16324697
    [Abstract] [Full Text] [Related]

  • 12. Subchronic caffeine administration sensitizes rats to the motor-activating effects of dopamine D(1) and D(2) receptor agonists.
    Cauli O, Morelli M.
    Psychopharmacology (Berl); 2002 Jul 28; 162(3):246-54. PubMed ID: 12122482
    [Abstract] [Full Text] [Related]

  • 13. Behavioral and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats.
    Neisewander JL, Lucki I, McGonigle P.
    J Pharmacol Exp Ther; 1991 May 28; 257(2):850-60. PubMed ID: 2033524
    [Abstract] [Full Text] [Related]

  • 14. Reversal of methamphetamine-induced behavioral sensitization by repeated administration of a dopamine D1 receptor agonist.
    Shuto T, Kuroiwa M, Hamamura M, Yabuuchi K, Shimazoe T, Watanabe S, Nishi A, Yamamoto T.
    Neuropharmacology; 2006 Jun 28; 50(8):991-7. PubMed ID: 16563442
    [Abstract] [Full Text] [Related]

  • 15. Behavioral differentiation of the stimulus properties of a dopaminergic D1 agonist from a D2 agonist.
    Cory-Slechta DA, Widzowski DV, Newland MC.
    J Pharmacol Exp Ther; 1989 Sep 28; 250(3):800-8. PubMed ID: 2789282
    [Abstract] [Full Text] [Related]

  • 16. Anatomical localization of SKF-38393-induced behaviors in rats using the irreversible monoamine receptor antagonist EEDQ.
    Neisewander JL, Ong A, McGonigle P.
    Synapse; 1995 Feb 28; 19(2):134-43. PubMed ID: 7725242
    [Abstract] [Full Text] [Related]

  • 17. Hippocampal modulation of locomotor activity induced by focal activation of postsynaptic dopamine receptors in the core of the nucleus accumbens.
    Rouillon C, Abraini JH, David HN.
    Hippocampus; 2007 Feb 28; 17(11):1028-36. PubMed ID: 17604350
    [Abstract] [Full Text] [Related]

  • 18. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats.
    Breese GR, Napier TC, Mueller RA.
    J Pharmacol Exp Ther; 1985 Aug 28; 234(2):447-55. PubMed ID: 3926987
    [Abstract] [Full Text] [Related]

  • 19. The D1 agonist SKF 38393 increases dopamine release in the developing rat striatum.
    Walters DE, Howard SG.
    Eur J Pharmacol; 1990 Aug 10; 184(2-3):257-64. PubMed ID: 2150376
    [Abstract] [Full Text] [Related]

  • 20. A vehicle injection into the right core of the nucleus accumbens both reverses the region-specificity and alters the type of contralateral turning elicited by unilateral stimulation of dopamine D2/D3 and D1 receptors in the left core of the nucleus accumbens.
    Ikeda H, Kotani A, Koshikawa N, Cools AR.
    Eur J Pharmacol; 2007 Dec 22; 577(1-3):64-70. PubMed ID: 17884038
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.